Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study (Q40112859)

17 September 2017

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study (English)

1 reference

17 September 2017

1 reference

1 reference

3

Bradley J Monk

1 reference

17 September 2017

John K Chan

1

1 reference

17 September 2017

Chunqiao Tian

2

1 reference

17 September 2017

Thomas Herzog

4

1 reference

17 September 2017

Daniel S Kapp

5

1 reference

17 September 2017

Jeffrey Bell

6

1 reference

17 September 2017

Robert C Young

7

1 reference

17 September 2017

Gynecologic Oncology Group

8

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

17 September 2017

1 reference

17 September 2017

112

1 reference

17 September 2017

2202-2210

1 reference

17 September 2017

10

1 reference

17 September 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

The National Cancer Data Base report on ovarian cancer treatment in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Prognostic factors for survival in stage I epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Natural history and prognosis of untreated stage I epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Epithelial ovarian carcinoma in the reproductive age group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Ovarian cancer in younger vs older women: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Survival and prognostic factors of early ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Treatment issues in clear cell carcinoma of the ovary: a different entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Interobserver variability in the interpretation of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

21 January 2018

Carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Prognostic factors and adjuvant treatment in early epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Risk of leukemia after platinum-based chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Prognostic value of DNA quantification in early epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Diagnostic value of peritoneal washings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

The clinical value of peritoneal lavage for cytologic examination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23390

7 January 2021

Identifiers

DOI

10.1002/CNCR.23390

1 reference

17 September 2017

1 reference